Core shell column in high-performance liquid chromatography for the determination of polar compounds; troxerutin and carbazochrome

Abstract

Background and Aims: The combination of troxerutin and carbazochrome has been found efficacious for non-surgical patients with acute uncomplicated hemorrhoids. Therefore it is essential to develop a simultaneous analysis method of those drug substances. This study explains a simple and selective HPLC method to analyze troxerutin and carbazohrome in tablets. Methods: The analysis was carried out using a core-shell pentafluorophenyl propyl polar column with a mobile phase consisting of (MeOH; % 5 HAc), (99.5:0.5 - V/V) at a flow rate of 0.25 mL/min. UV detection was set to 350 nm. Results: The standard calibration curve was established between 1.00-20.00 μg/mL for troxerutin; 0.05-1.00 μg/mL for carbazochrome. LOD and LOQ were found to be 0.65 μg/mL and 1.00 μg/mL for troxerutin and 0.01 μg/mL and 0.05 μg/mL for carbazochrome, respectively. Conclusion: The proposed method was validated for specificity, linearity, accuracy, precision, LOQ and LOD and then successfully applied for the analysis of these substances in tablets.

Keywords

• Troxerutin,carbazochrome,high performance liquid chromatography,core-shell column,tablet

References

1. • Abdelrahman, M. M., Abdelaleem, E. A., Ali, N. W., & Emam, R. A. (2016). Simultaneous determination of Carbazochrome and Troxerutin in their binary mixture by HPLC and HPTLC-Densitometric methods. Bulletin of Faculty of Pharmacy, Cairo University, 54(1), 67–75.
2. • Basile, M., Gidaro, S., Pacella, M., Biffignandi, P. M., & Gidaro, G. S. (2001). Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: A randomized, double-blind, placebo-controlled, phase IV study. Current Medical Research and Opinion, 17(4), 256–261.
3. • Chen, Y. H., Ren, K.,Tian F. S., Zhu, K. K., & Hu, X. Y. (2015). Spectrofluorimetric and spectrophotometric determination of troxerutin in pharmaceutical preparations. Asian Journal of Chemıstry, 27(5), 1854–1856.
4. • Cui, X., Zhang, M., Guan, X., Yin, L., Sun, Y., Fawcett, J. P., & Gu, J. (2011). LC–MS–MS determination of troxerutin in plasma and its application to a pharmacokinetic study. Chromatographia, 73(1), 165–169.
5. • European Medicines Agency. (1995). ICH Q2 (R1) validation of analytical procedures: Text and methodology. Retrieved from https://www. ema.europa.eu/documents/scientific-guideline/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf
6. • European Medicines Agency. (2011). Guideline on bioanalytical method validation. Retrived from https://www.ema.europa.eu/ en/documents/scientific-guideline/guideline-bioanalyticalmethod-validation_en.pdf
7. • Gan, X., Liu, S., Liu, Z., Hu, X., Cui, Z., & Wang, Y. (2012). Determination of carbazochrome by fluorescence quenching method. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 97, 161–166.
8. • Guo, H-Z., Ron, C., Bı, K-S., & Sun, Y-Q. (2004). Determination of troxerutin in venoruton injections and venoruton tabletsby short capillary zone electrophoresis. Chinese Journal of Pharmaceutical Analysis, 24(5), 457–459.

9. • Hayes, R., Ahmed, A., Edge, T., & Zhang, H. (2014). Core-shell particles: Preparation, fundamentals and applications in high performance liquid chromatography. Journal of Chromatography A, 1357, 36–52.
10. • Hepsebah, N., Nihitha, D., & Kumar, A. A. (2014). Reverse phase HPLC method development and validation for the simultaneous quantitative estimation of Troxerutin and calcium dobesilate in tablets. International Journal of Pharmacy and Pharmaceutical Sciences, 6(1), 333–339.
11. • Hu, X., Zheng, Y., Wu, G., Liu, J., Zhu, M., Zhou, H. ... Shen-Tu, J. (2014). Optimization of solid phase extraction clean up and validation of quantitative determination of carbazochrome sodium sulfonate in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 951–952, 1–6.
12. • Joseph, J., & Deepthi, K. (2015). Development and validation of analytical methods for the simultaneous estimation of troxerutin and calcium dobesilate in bulk and pharmaceutical dosage form. Indo American Journal of Pharmaceutical Research, 5(9), 1–7.
13. • Khattab, F. I., Ramadan, N. K., Hegazy, M. A., Al-Ghobashy, M. A., & Ghoniem, N. S. (2015). Validated spectrophotometric methods for simultaneous determination of troxerutin and carbazochrome in dosage form. Spectrochim Acta A Mol Biomol Spectroscopy, 139, 206–213.
14. • Reviewer Guidance, Validation of Chromatographic Methods. FDA (Center for Drug Evaluation and Research, U.S. Food and Drug Administration). (1994). https://www.fda.gov/downloads/Drugs/ Guidances/UCM134409.pdf
15. • Song, M., Zhao, H., Wang, L., Yang, L., Hang, T., & Wen, A. (2010). Development and validation of a robust LC-MS-MS with atmospheric pressure chemical ionization for quantitation of carbazochrome sodium sulfonate in human plasma: Application to a pharmacokinetic study. Biomed Chromatography, 24(9), 990–999.
16. • Squadrito, F., Altavilla, D., & Oliaro Bosso, S. (2000). Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids. European Review for Medical and Pharmacological Sciences, 4(1–2), 21–24.
17. • Wang, L. Fu, Z., & Wang, Y. (2011). Cation exchange solid-phase extraction coupled with flow injection chemiluminescent analysis for detection of carbazochrome. Chinese Journal of Pharmaceutical Analysis, 31(10), 1934–1937.
18. • Wu, H., & Liu, F. (2008). Determination of carbazochrome sodium sulfonate for injection by UV spectrophotometry [J]. Anhui Medical and Pharmaceutical Journal, 1(12), 18–19.
19. • Yang, G. J., Liu, P., Qu, X. L., Xu, M. J., Qu, Q. S., Wang, C. Y. … Wang Z. Y. (2007). The simultaneous separation and determination of six flavonoids and troxerutin in rat urine and chicken plasma by reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. J Chromatography B Analytical Technologies in Biomedical Life Sciences, 856(1–2), 222–228.